INCYTE CORPORATION Unrealized Gain (Loss) on Securities
INCYTE CORPORATION (INCY) reported Unrealized Gain (Loss) on Securities of -$24.27 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Income Statement › Other Income
us-gaap:UnrealizedGainLossOnSecurities · last filed 2018-02-15
- INCYTE CORPORATION unrealized gain (loss) on securities for the quarter ending 2017-12-31 was -$21.93M.
- INCYTE CORPORATION unrealized gain (loss) on securities for the quarter ending 2017-09-30 was $23.05M, a 5.17% decline year-over-year.
- INCYTE CORPORATION unrealized gain (loss) on securities for the quarter ending 2017-06-30 was -$19.57M.
- INCYTE CORPORATION unrealized gain (loss) on securities for the quarter ending 2017-03-31 was -$5.81M.
- INCYTE CORPORATION unrealized gain (loss) on securities for fiscal 2017 was -$24.27M.
- INCYTE CORPORATION unrealized gain (loss) on securities for fiscal 2016 was -$3.26M.
- INCYTE CORPORATION unrealized gain (loss) on securities for fiscal 2015 was -$4.58M.
| Period end | Unrealized Gain (Loss) on Securities 3 month | Unrealized Gain (Loss) on Securities 6 month | Unrealized Gain (Loss) on Securities 9 month | Unrealized Gain (Loss) on Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$21.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.11M derived: sum of 2 quarters · filed 2018-02-15 | -$18.46M derived: sum of 3 quarters · filed 2018-02-15 | -$24.27M 10-K · filed 2018-02-15 |
| 2017-09-30 | $23.05M 10-Q · filed 2017-10-31 | $3.47M derived: sum of 2 quarters · filed 2017-10-31 | -$2.34M 10-Q · filed 2017-10-31 | -$26.10M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | -$19.57M 10-Q · filed 2017-08-01 | -$25.39M 10-Q · filed 2017-08-01 | -$49.15M derived: sum of 3 quarters · filed 2018-02-15 | -$24.84M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$5.81M 10-Q · filed 2017-05-04 | -$29.57M derived: sum of 2 quarters · filed 2018-02-15 | -$5.27M derived: sum of 3 quarters · filed 2018-02-15 | -$6.13M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | -$23.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $543.00K derived: sum of 2 quarters · filed 2018-02-15 | -$311.00K derived: sum of 3 quarters · filed 2018-02-15 | -$3.26M 10-K · filed 2018-02-15 |
| 2016-09-30 | $24.30M 10-Q · filed 2017-10-31 | $23.45M derived: sum of 2 quarters · filed 2017-10-31 | $20.50M 10-Q · filed 2017-10-31 | $20.03M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$854.00K 10-Q · filed 2017-08-01 | -$3.80M 10-Q · filed 2017-08-01 | -$4.27M derived: sum of 3 quarters · filed 2018-02-15 | -$35.56M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$2.95M 10-Q · filed 2017-05-04 | -$3.42M derived: sum of 2 quarters · filed 2018-02-15 | -$34.70M derived: sum of 3 quarters · filed 2018-02-15 | -$7.53M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$31.75M derived: sum of 2 quarters · filed 2018-02-15 | -$4.58M derived: sum of 3 quarters · filed 2018-02-15 | -$4.58M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$31.29M 10-Q · filed 2016-11-01 | -$4.12M derived: sum of 2 quarters · filed 2016-11-01 | -$4.12M 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $27.17M 10-Q · filed 2016-08-09 | $27.17M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |